Cyclic Peptide Anti-Inflammatory Drugs Can Be Delivered Through the Skin

Small macrocyclic C5a complement antagonists achieved meaningful transdermal delivery in rats, demonstrating that cyclic peptide drugs can penetrate skin — opening topical administration for anti-inflammatory peptide therapy.

Proctor, Lavinia M et al.·Advances in experimental medicine and biology·2006·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-01178Animal StudyPreliminary Evidence2006RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Macrocyclic C5a antagonists achieved pharmacologically active transdermal penetration in rats, with measurable anti-inflammatory effects from topical application — establishing the feasibility of transdermal delivery for cyclic peptide anti-inflammatory drugs.

Key Numbers

How They Did This

animal-study study on cyclic-peptides, inflammation.

Why This Research Matters

Relevant for cyclic-peptides, inflammation, peptide-delivery.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Macrocyclic C5a antagonists achieved pharmacologically active transdermal penetration in rats, with measurable anti-inflammatory effects from topical
Evidence Grade:
preliminary evidence.
Study Age:
Published in 2006.
Original Title:
Transdermal pharmacology of small molecule cyclic C5a antagonists.
Published In:
Advances in experimental medicine and biology, 586, 329-45 (2006)
Database ID:
RPEP-01178

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Cyclic Peptide Anti-Inflammatory Drugs Can Be Delivered Through the Skin

What was found?

Small macrocyclic C5a complement antagonists achieved meaningful transdermal delivery in rats, demonstrating that cyclic peptide drugs can penetrate skin — opening topical administration for anti-inflammatory peptide therapy.

Read More on RethinkPeptides

Cite This Study

RPEP-01178·https://rethinkpeptides.com/research/RPEP-01178

APA

Proctor, Lavinia M; Woodruff, Trent M; Sharma, Prakirti; Shiels, Ian A; Taylor, Stephen M. (2006). Transdermal pharmacology of small molecule cyclic C5a antagonists.. Advances in experimental medicine and biology, 586, 329-45.

MLA

Proctor, Lavinia M, et al. "Transdermal pharmacology of small molecule cyclic C5a antagonists.." Advances in experimental medicine and biology, 2006.

RethinkPeptides

RethinkPeptides Research Database. "Transdermal pharmacology of small molecule cyclic C5a antago..." RPEP-01178. Retrieved from https://rethinkpeptides.com/research/proctor-2006-transdermal-pharmacology-of-small

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.